BAT1006
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model[1].
Product Specifications
UNSPSC
12352203
Target
EGFR
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
[BAT1006]
References & Citations
[1]Xingxing Mei, et al. Abstract CT189: A phase I study of BAT1006, a novel anti-HER2 antibody, in patients with locally advanced/metastatic solid tumors. Cancer research. Cancer Res (2023) 83 (8_Supplement) : CT189.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
